Vabysmo (faricimab-svoa)

Vabysmo (faricimab‑svoa) is covered only for FDA‑approved indications — neovascular (wet) age‑related macular degeneration (nAMD) and diabetic macular edema (DME); off‑label uses are excluded. Coverage requires administration by or under an ophthalmologist, documentation of diagnosis and dosing/administration per limits (nAMD: 6 mg intravitreal ≤ every 4 weeks for four doses then ≤ every 8 weeks; DME: 6 mg intravitreal ≤ every 4 weeks), a 12‑month approval period, and fulfillment of additional indication‑specific coverage criteria.

"Vabysmo is indicated for the treatment of patients with: Diabetic macular edema (DME)"

Sign up to see full coverage criteria, indications, and limitations.